Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease

• Váldodahkkit: S. K. Zyryanov (Dahkki), I. N. Dyakov (Dahkki), A. V. Veselov (Dahkki), V. N. Kashnikov (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Izdatelstvo OKI, 2018-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Aim. Evaluation of the impact on the budget of the program for the provision of necessary medications (ONLS program) for the inclusion of a new drug vedolizumab for the treatment of adult patients with moderate or severe active ulcerative colitis (UC) and moderate or severe active Crohn's disea...